Blog
May 16, 2023
Blog
Common sense suggests that if a lower cost product is on the market, then consumers should be able to choose... Read more »
March 3, 2023
Blog
Event
AAM’s annual conference, Access!, was held February 13-15 in Orlando, Florida, where Biosimilars Council members were joined by leaders from... Read more »
February 21, 2023
Blog
The biosimilars market has reached a new milestone, with the first-ever biosimilar to Humira (adalimumab) recently launching, and as many... Read more »
November 23, 2022
Blog
Event
Earlier this month, AAM and the Biosimilars Council hosted guests in North Bethesda, Maryland for the 2022 GRx+Biosims Conference. This... Read more »
October 25, 2022
Blog
Each year, more biosimilars continue to reach new patients, delivering greater savings to them, taxpayers, and the American healthcare system.... Read more »
October 12, 2022
Blog
As trusted partners for patients, pharmacists have a critical role to play in educating consumers about biosimilar medicines. Biosimilars are... Read more »
October 6, 2022
Blog
Although biosimilars have made great strides in the last year, there remains much work to be done. This point is... Read more »
August 15, 2022
Blog
Since the first biosimilar was approved in the U.S. in 2015, these life savings therapies have provided nearly $13 billion... Read more »
July 26, 2022
Blog
Congress is actively seeking to advance legislation to allow the Medicare program to “negotiate” the prices of brand drugs. However,... Read more »
May 23, 2022
Blog
On May 23, 2022, the Association for Accessible Medicines and its Biosimilars Council urged the Federal Trade Commission (FTC) to... Read more »
May 20, 2022
Blog
Biosimilar medicines are revolutionary therapeutics that treat patients at a fraction of the cost of brand-name biologics. However, public awareness... Read more »
April 8, 2022
Blog
Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many PBMs... Read more »
March 23, 2022
Blog
Greg, 37, of Los Angeles, CA., spends most of his time hiking, running and lifting weights, but his greatest passion... Read more »
March 15, 2022
Blog
Eileen, 28, lives in New York City and is pursuing her dream of a career in musical theater. Her stage... Read more »
March 11, 2022
Blog
This year, Congress will consider legislation that codifies performance goals for the review of drug applications by the U.S. Food... Read more »
February 24, 2022
Blog
Event
February 14-16, AAM and its Biosimilars Council welcomed attendees to Orlando, Florida for Access! 2022, the generics and biosimilars industry’s... Read more »
February 4, 2022
Blog
Last year was full of exciting developments for patients who rely on biosimilars. Here’s a look at what we’re working... Read more »
February 2, 2022
Blog
On February 2 we mark Rheumatoid Arthritis (RA) Awareness Day and shine a light on the roughly 1.5 million Americans... Read more »
December 20, 2021
Blog
This week, we learned that employers experienced a 6.3% jump in health benefit costs last year.1Findings such as these, paired with... Read more »
December 3, 2021
Blog
The biosimilars industry is proving that market competition works to drive down drug costs and increase patient access to medicines.... Read more »
October 28, 2021
Blog
Biosimilar medicines are increasingly becoming an essential fixture in health care, reducing prices and increasing patient access. This is especially... Read more »
October 14, 2021
Blog
Since the enactment of the Biologics Price Competition and Innovation Act in 2010, patients with complex disease have been eager... Read more »
July 27, 2021
Blog
Since the biosimilars pathway (BPCIA) was established in 2010, 30* biosimilars have been approved. However, due to significant barriers to... Read more »
July 1, 2021
Blog
Today, a group of organizations representing patients, employers, taxpayers, providers, communities of color and consumer groups sent a letter thanking... Read more »
June 28, 2021
Blog
Biosimilar competition has the potential to provide greater access to important treatments for America’s patients and cost savings for the… Read more »
June 11, 2021
Blog
In recent years, significant attention has been given to the advent of biosimilars, a new class of medicines approved by... Read more »
May 7, 2021
Blog
Biosimilars were first introduced in the United States about five years ago to treat patients with various medical conditions including... Read more »
April 20, 2021
Blog
Access!, AAM’s annual meeting for the generics and biosimilars industry, brings policymakers, influential speakers and industry leaders together to share... Read more »
March 25, 2021
Blog
Since the first biosimilar launched in the U.S. market five years ago, the U.S. Food and Drug Administration (FDA) has... Read more »
February 4, 2021
Blog
In 2020, cancer claimed the lives of 600,000 Americans. According to the American Cancer Society (ACS CAN), there are approximately... Read more »
December 22, 2020
Blog
Biosimilar medicines are safe, effective alternative versions of existing brand biologic medicines (known as “reference products”) with scientifically comparable quality, safety... Read more »
November 16, 2020
Blog
Biosimilars are critical to the discussion around health care and its rising costs, as they have the potential to save... Read more »
November 10, 2020
Blog
Today, the U.S. Supreme Court will hear arguments on the constitutionality of the Affordable Care Act (ACA). Although the case... Read more »
October 26, 2020
Blog
The Biologics Price Competition and Innovation Act of 2010 (BPCIA) provides a framework for biosimilars approval, adoption and access in... Read more »
October 12, 2020
Blog
Biosimilar developers must combat several obstacles in bringing a product to market, including patent litigations like this, while brand companies... Read more »
October 5, 2020
Blog
Before biologic drugs are ready to be used by patients, scientists and providers spend years developing, researching, and testing them... Read more »
September 28, 2020
Blog
According to a report on biosimilars cost savings in the U.S., biosimilars could lead to over $54 billion in savings... Read more »
September 21, 2020
Blog
Biosimilars are biologic medicines that are highly similar to a previously approved reference biologic currently on the market. But what does that short definition of a biosimilar actually mean?... Read more »
April 6, 2020
Blog
More than 180 million Americans receive health care benefits through their employer, with large employers paying more than 80 percent... Read more »
March 4, 2020
Blog
According to a study released by Pacific Research Institute, biosimilars have the potential to bring significant savings to both state... Read more »
January 30, 2020
Blog
2019 was a whirlwind year for biosimilars, highlighted by a record 10 U.S. Food and Drug Administration (FDA) approvals and... Read more »
November 21, 2019
Blog
Event
Earlier this month the Association for Accessible Medicines (AAM) and its Biosimilars Council hosted the second annual GRx+Biosims Conference for... Read more »
October 2, 2019
Blog
When it comes to ensuring medicines — including biosimilars — are safe and effective for patients, the FDA remains the… Read more »
June 24, 2019
Blog
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »
July 29, 2019
Blog
Hillel Cohen Executive Director, Scientific Affairs, Sandoz, Inc. Written by Hillel P. Cohen Biosimilars are a competitive, effective alternative for... Read more »
May 9, 2019
Blog
In a recent for Drug Store News, Chip Davis, President and CEO for the Association of Accessible Medicines, discusses the... Read more »
May 9, 2019
Blog
A recent series in Health Affairs questioned whether competition from biosimilar medicines is a viable path to providing relief from… Read more »
April 22, 2019
Blog
The Biologic Patent Transparency Act, introduced in March and sponsored by Senators Susan Collins (R-ME) and Tim Kaine (D-VA), would... Read more »
February 22, 2019
Blog
Earlier this month in New Orleans, the Association for Accessible Medicines and its Biosimilars Council hosted our annual Access! Conference. Attendees from... Read more »
February 4, 2019
Blog
Actions by branded companies to undermine proven safe, effective biosimilars hurt patients. U.S. Food & Drug Administration Commissioner Scott Gottlieb... Read more »
December 10, 2018
Blog
On Friday, December 14, the U.S. Food and Drug Administration (FDA) announced its sixteenth biosimilar approval for biosimilar trastuzumab, a drug used in... Read more »
November 18, 2018
Blog
The American Society of Hematology (ASH) has added to its eLearning platform a new educational course titled “Biosimilars: A New Era of Hematology/Oncology... Read more »
November 15, 2018
Blog
The burden of high prescription medicine costs for America’s patients continues to drive much of the national health care conversation and... Read more »
November 14, 2018
Blog
Scott Knoer, M.S., Pharm.D, serves as Chief Pharmacy Officer for the Cleveland Clinic, one of the largest hospitals nationwide. In... Read more »
November 13, 2018
Blog
A recent Italian study published in Frontiers in Public Health examined the effect of including a pharmacist in the Department of Abdominal... Read more »
October 16, 2018
Blog
Pharmacists are among the most trusted health care professionals in America. Millions of patients rely on their pharmacist for guidance... Read more »
September 25, 2018
Blog
IQVIA, a leading healthcare research company, recently released a new report, “Advancing Biosimilar Sustainability in Europe,” which examines the status of biosimilars... Read more »
September 11, 2018
Blog
The Biosimilars Council's parent organization, the Association for Accessible Medicines (AAM), is active in promoting education around a variety of... Read more »
September 2, 2018
Blog
Seventeen stakeholder groups representing a variety of healthcare industry’s sent a letter to FDA, urging greater clarity on interchangeability guidance... Read more »
August 31, 2018
Blog
This week, the United States announced that it has reached a preliminary agreement with our North American counterparts, Canada and... Read more »
August 20, 2018
Blog
This week, the United States announced that it has reached a preliminary agreement with our North American counterparts, Canada and... Read more »
May 4, 2018
Blog
Last Friday, The Biosimilars Council hosted a congressional briefing titled “Biosimilars: The Challenges and Promise of Patient Access.” AAM’s Craig Burton moderated a discussion... Read more »
April 13, 2018
Blog
Science, Data and FDA Support the Safety and Efficacy of Biosimilars for Patients As the biosimilars market begins to expand... Read more »
March 15, 2018
Blog
The Naming of Biosimilar Medicines Worldwide Should Promote Patient Safety and Prescriber Confidence
In response to the growing number of biosimilar approvals and increased acceptance of their safety and efficacy a number of... Read more »
March 1, 2018
Blog
Today’s healthcare arsenal includes biological products, or biologics, that are used in the treatment, prevention or diagnosis of diseases and... Read more »
February 15, 2018
Blog
2017 was a watershed year for patients seeking affordable alternatives to expensive biologic medicines . The number of FDA-approved biosimilars more... Read more »
February 7, 2018
Blog
Since their first use in the 1980s, biologic medicines have grown to become an indispensable tool in modern medicine. Advancements... Read more »
December 19, 2017
Blog
For anyone following the nascent biosimilars market in the U.S., 2017 has been a busy year: the Centers for Medicare... Read more »
December 1, 2017
Blog
Biosimilars hold great promise for patients seeking access to more affordable versions of critical medicines, but also for a health care system facing unsustainable, increasing costs. One of the most immediate challenges to biosimilars uptake in the United State sis the lack of […]
October 4, 2017
Blog
In the fast-paced world of health care, the role of the patient continues to evolve from passive to active. One of the most pressing issues patients face is the cost of their medications, which can serve as a significant barrier to access, especially for expensive brand-name biologic medicines[…]
September 1, 2017
Blog
Event
Join us as we examine the promise of biosimilars in the United States and discuss how best to ensure patient... Read more »
July 25, 2017
Blog
This week, Avalere Health published new research that found 81% of health insurers are covering at least one of the... Read more »
June 27, 2017
Blog
On June 7th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Update on Biosimilars” at the Newseum in Washington, D.C. The third in a series of Atlantic biosimilars briefings underwritten by The Biosimilars Council […]
June 6, 2017
Blog
Biosimilars not only have the unique ability to provide patients with much-needed access to lower-cost complex therapies, but also offer the potential for billions in patient, insurer and health system savings. But there are barriers […]
May 25, 2017
Blog
Working in coordination with The Atlantic, an award-winning publication that covers politics, business, and technology, The Biosimilars Council will continue its efforts to educate consumers about biosimilars by bringing together key stakeholders to debate the state and future of biosimilars […]
May 8, 2017
Blog
The country has undergone a great deal of change from December to today – but one thing that has not changed is that Americans want action to bring down the price of prescription drugs. A recent Kaiser Health Tracking Poll showed that over 60% of Americans believe lowering the cost of […]
March 28, 2017
Blog
On March 15th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Briefing” at the Newseum in Washington, D.C. Underwritten by The Biosimilars Council, more than 100 influencers from across the […]